Form D · Pharmaceuticals
Item 9 Labs Corp.
Phoenix, AZ · CIK 0001500123
Offering snapshot reported Feb 26, 2021 · SEC filing
- Reported sold
- $12.1M Offering amount: $13M
- Investors reported
- 122 Form D · investor count
- Minimum accepted
- $85K Reported outside-investor minimum
- First sale
- Nov 13, 2020 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$2,514,850 → $12,124,446
- Reported investors21 → 122
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 26, 2021 | Amendment | $12,124,446 | $9,609,596vs Dec 30, 2020 | 122 | SEC filing |
| Dec 30, 2020 | Initial | $2,514,850 | No comparison | 21 | SEC filing |
| Dec 14, 2018 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Apr 5, 2018 | Initial | $1,090,000 | No comparison | 53 | SEC filing |
| Sep 25, 2015 | Amendment | $185,000 | $0vs Sep 16, 2015 | 3 | SEC filing |
| Sep 16, 2015 | Initial | $185,000 | No comparison | 3 | SEC filing |
| Jul 25, 2013 | Initial | $65,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-384703
Board of Directors increased Total offering from $8,500,000 to $13,000,000
Source: Form D, filed Feb 26, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Douglas Bowden | Director |
| Andrew Bowden | Director, Executive |
| Daniel Cohen | Director, Executive |
| Sara Gullickson | Director, Executive |
| Michael Keskey | Director |
| Robert Mikkelsen | Executive |
| Robert Mikkelson | Executive |
| Ronald Miller | Director |
| Ron Miller | Director |
| Ronald L Miller, Jr. | Director |
| Jeffrey Rassas | Director, Executive |
| Bryce Skalla | Director, Executive |
| Jessica Smith | Executive |
| Christopher Wolven | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2727 North 3 Rd Street Suite 201
Phoenix, AZ, 85004
Phoenix, AZ, 85004